Bliss GVS Pharma Ltd. | Mutual Funds
Mutual Funds that own Bliss GVS Pharma Ltd.
Fidelity Low Priced Stock Fund
4,600,000
4.46%
0
0.04%
04/30/2018
DFA Emerging Markets Core Equity Portfolio
599,112
0.57%
144,930
0.01%
04/30/2018
276,498
0.27%
0
0.04%
07/31/2018
DFA Emerging Markets Small Cap Series
213,683
0.21%
84,354
0.01%
01/31/2018
212,366
0.21%
0
0.26%
09/05/2018
WisdomTree India Earnings Fund
102,818
0.1%
1,360
0.02%
09/06/2018
Fidelity Series Intrinsic Opportunities Fund
100,000
0.1%
0
0%
04/30/2018
TIFF Multi Asset Fund
55,101
0.05%
0
0.01%
06/30/2018
Dimensional Funds ICVC - Emerging Markets Core Equity Fund
18,884
0.02%
0
0%
12/31/2017
DFA TA World (ex-US) Core Equity Portfolio
17,529
0.02%
0
0%
04/30/2018
| Address |
102, Hyde Park
Mumbai Maharashtra 400072
India
|
|
Employees
|
- |
| Website |
http://www.blissgvs.com |
| Updated |
09/14/2018 |
| Bliss GVS Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. Its products include capsules; creams, gels, and ointment; dry powder for injection and oral suspension; effervescent tablets; eye and ear drops; injection; liquid preparations; lotions; lozenges; nasal solution; oral solids; parenterals; pessaries; sachets; soft gelatin capsules; suppositories; suspension; syrups; tablets; and topical preparations. The company was founded on December 11, 1984 and is headquartered in Mumbai, India. |
